VRx 3996

Drug Profile

VRx 3996

Alternative Names: CHR-3996; VRx-3996

Latest Information Update: 10 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chroma Therapeutics
  • Developer Chroma Therapeutics; Viracta Therapeutics
  • Class Antineoplastics; Pyrimidines; Quinolines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I Solid tumours
  • Preclinical Gastric cancer; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
  • Phase Unknown Lymphoma

Most Recent Events

  • 04 Apr 2017 VRx 3996 licensed to NantKwest worldwide
  • 04 Apr 2017 NantKwest plans clinical trials for VRx 3996 in combination with aNK, haNK and taNK NK cell therapy
  • 06 Dec 2016 Safety results from a phase I/II trial in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top